지혈 소개

During the vascular phase, blood vessels quickly constrict in a process called vasoconstriction to reduce blood flow to the injury site. This rapid narrowing minimizes blood loss and is the first defensive response triggered by vascular injury, setting the stage for subsequent hemostasis phases.

Platelets adhere to exposed collagen from damaged endothelial cells and become activated. They then aggregate at the injury site, releasing compounds that attract additional platelets and clotting factors. This process forms a loose platelet plug that acts as a temporary seal to control bleeding.

Clotting factors, including fibrinogen, are plasma proteins that convert into fibrin strands during the coagulation phase. These insoluble fibrin strands form a meshwork that solidifies the platelet plug into a stable clot, reinforcing the temporary seal and preventing further blood loss.

Hemostasis is highly localized because it is triggered only at the injury site and governed by clotting factors and platelets present in the immediate area. This targeted response prevents unnecessary clotting throughout the circulatory system while maintaining blood fluidity elsewhere in the vascular network.

Platelet aggregation creates an initial loose plug at the injury site. Simultaneously, activated platelets release clotting factors that trigger the coagulation phase, converting fibrinogen to fibrin. This fibrin reinforces the platelet plug, transforming it into a stable, insoluble clot that effectively seals the vessel.

Hemostasis is a carefully controlled response that occurs only when vascular injury triggers the cascade. Under normal conditions, clotting factors remain inactive in plasma, and platelets circulate without aggregating. This balance ensures blood remains fluid and flows freely through the circulatory system until injury necessitates clot formation.

Hemostasis progresses through three phases: the vascular phase involves vasoconstriction to reduce blood flow; the platelet phase includes platelet adhesion, activation, and aggregation forming a plug; and the coagulation phase converts fibrinogen to fibrin, creating a stable clot that reinforces the platelet plug and prevents further bleeding.